Prognostic significance of BLK expression in R-CHOP treated diffuse large B-cell lymphoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The aim of the present study was to evaluate the prognostic significance of B-cell lymphocyte kinase (BLK) expression for survival outcomes in diffuse large B-cell lymphoma (DLBCL) patients treated with R-CHOP.Methods: We retrospectively analyzed the medical records of 89 patients from two tertiary referral hospitals. The expression of BLK, SYK, and CDK1 were evaluated in a semiquantitative method using an H-score, and the proportions of BCL2 and C-MYC were evaluated.Results: A total of 89 patients received R-CHOP chemotherapy as a first-line chemotherapy. The expression rates of BLK in tumor cells was 39.2% (n = 34). BLK expression status was not significantly associated with clinical variables; however, BLK expression in tumor cells was significantly associated with the expression of both C-MYC and BCL2 (p = .003). With a median follow-up of 60.4 months, patients with BLK expression had significantly lower 5-year progression-free survival (PFS) and overall survival rates (49.8% and 60.9%, respectively) than patients without BLK expression (77.3% and 86.7%, respectively). In multivariate analysis for PFS, BLK positivity was an independent poor prognostic factor (hazard ratio, 2.208; p = .040).Conclusions: Here, we describe the clinicopathological features and survival outcome according to expression of BLK in DLBCL. Approximately 39% of DLBCL patients showed BLK positivity, which was associated as a predictive marker for poor prognosis in patients who received R-CHOP chemotherapy.
Abstract
Background: The aim of the present study was to evaluate the prognostic significance of B-cell lymphocyte kinase (BLK) expression for survival outcomes in diffuse large B-cell lymphoma (DLBCL) patients treated with R-CHOP.Methods: We retrospectively analyzed the medical records of 89 patients from two tertiary referral hospitals. The expression of BLK, SYK, and CDK1 were evaluated in a semiquantitative method using an H-score, and the proportions of BCL2 and C-MYC were evaluated.Results: A total of 89 patients received R-CHOP chemotherapy as a first-line chemotherapy. The expression rates of BLK in tumor cells was 39.2% (n = 34). BLK expression status was not significantly associated with clinical variables; however, BLK expression in tumor cells was significantly associated with the expression of both C-MYC and BCL2 (p = .003). With a median follow-up of 60.4 months, patients with BLK expression had significantly lower 5-year progression-free survival (PFS) and overall survival rates (49.8% and 60.9%, respectively) than patients without BLK expression (77.3% and 86.7%, respectively). In multivariate analysis for PFS, BLK positivity was an independent poor prognostic factor (hazard ratio, 2.208; p = .040).Conclusions: Here, we describe the clinicopathological features and survival outcome according to expression of BLK in DLBCL. Approximately 39% of DLBCL patients showed BLK positivity, which was associated as a predictive marker for poor prognosis in patients who received R-CHOP chemotherapy.
참고문헌 (39)
- Coiffier B, "Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l’Adulte", Blood, 116, pp.2040~2045 (2010)
- Coiffier B, "Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin’s lymphoma", Semin Oncol, 29, pp.18~22 (2002)
- Sehn LH, "The revised International Prognostic Index(R-IPI)is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP", Blood, 109, pp.1857~1861 (2007)
- Staiger AM, "Clinical impact of the cell-oforigin classification and the MYC", BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German high-grade non-Hodgkin’s Lymphoma Study Group, 2017, pp.35, 2515~2526
- Masir N, "Diffuse large B-cell lymphoma in Southeast Asian cohort : expression patterns of B-cell receptor(BCR)repertoire and its linkage with molecular subtypes and response to R-CHOP therapy", J Clin Pathol, 72, pp.630~635 (2019)
- Krejsgaard T, "Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma", Blood, 113, pp.5896~5904 (2009)
- Drebin JA, "Molecular cloning and chromosomal localization of the human homologue of a B-lymphocyte specific protein tyrosine kinase(blk)", Oncogene, 10, pp.477~486 (1995)
- Zhang X, "Src family protein kinase controls the fate of B cells in autoimmune diseases", Inflammation, 44, pp.423~433 (2021)
- Dymecki SM, "Structure and developmental regulation of the B-lymphoid tyrosine kinase gene blk", J Biol Chem, 267, pp.4815~4823 (1992)
- Tretter T, "Mimicry of pre-B cell receptor signaling by activation of the tyrosine kinase Blk", J Exp Med, 198, pp.1863~1873 (2003)
- Zhang M, "The pre-B cell receptor and its function during B cell development", Cell Mol Immunol, 1, pp.89~94 (2004)
- Wang WG, "MYC Protein-positive diffuse large B-cell lymphoma features an activated B-cell receptor signal pathway", Am J Surg Pathol, 41, pp.541~549 (2017)
- Chen L, "SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma", Blood, 111, pp.2230~2237 (2008)
- Efremov DG, "Mechanisms of B cell receptor activation and responses to B cell receptor inhibitors in B cell malignancies", Cancers(Basel), 12, pp.1396~ (2020)
- 서철원, "Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party", Blood Research, 48(3), pp.171~177 (2013), 대한혈액학회
- "International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma", N Engl J Med, 329, pp.987~994 (1993)
- Johnson NA, "Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone", J Clin Oncol, 30, pp.3452~3459 (2012)
- Bogusz AM, "Diffuse large B-cell lymphoma with concurrent high MYC and BCL2expression shows evidence of active B-cell receptor signaling by quantitative immunofluorescence", PLoS One, 12, pp.e0172364~ (2017)
- Bankhead P, "QuPath : Open source software for digital pathology image analysis", Sci Rep, 7, pp.16878~ (2017)
- Mutzbauer G, "SYK expression in monomorphic epitheliotropic intestinal T-cell lymphoma", Mod Pathol, 31, pp.505~516 (2018)
- Nagato T, "Cyclin-dependent kinase 1 and survivin as potential therapeutic targets against nasal natural killer", T-cell lymphoma, 2019, pp.99, 612~624
- Chen X, "The clinical significance of CDK1expression in oral squamous cell carcinoma", Med Oral Patol Oral Cir Bucal, 20, pp.e7~e12 (2015)
- Montero-Ruiz O, "Expression of RUNX1 isoforms and its target gene BLK in childhood acute lymphoblastic leukemia", Leuk Res, 36, pp.1105~1111 (2012)
- Petersen DL, "B-lymphoid tyrosine kinase(Blk)is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma(CTCL)", Leukemia, 28, pp.2109~2112 (2014)
- Bagnato G, "Nuclear functions of the tyrosine kinase Src", Int J Mol Sci, 21, pp.2675~ (2020)
- Zhou F, "Nucleocytoplasmic trafficking of the Syk protein tyrosine kinase", Mol Cell Biol, 26, pp.3478~3491 (2006)
- Zeng C, "B-cell lymphocyte kinase polymorphisms rs13277113, rs2736340, and rs4840568 and risk of autoimmune diseases: a meta-analysis", Medicine(Baltimore), 96, pp.e7855~ (2017)
- Petersen DL, "A novel BLKinduced tumor model", Tumour Biol, 39, pp.1010428317714196~ (2017)
- Cheng S, "SYK inhibition and response prediction in diffuse large B-cell lymphoma", Blood, 118, pp.6342~6352 (2011)
- Davis RE, "Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma", Nature, 463, pp.88~92 (2010)
- Xu N, "Akt : a double-edged sword in cell proliferation and genome stability", J Oncol, 2012, pp.951724~ (2012)
- Wang J, "AKT Hyperactivation and the potential of AKT-targeted therapy in diffuse large B-cell lymphoma", Am J Pathol, 187, pp.1700~1716 (2017)
- Xia Y, "The spectrum of MYC alterations in diffuse large B-cell lymphoma", Acta Haematol, 143, pp.520~528 (2020)
- Ondrisova L, "Genetic and non-genetic mechanisms of resistance to BCR signaling ihibitors in B cell malignancies", Front Oncol, 10, pp.591577~ (2020)
- Kuo HP, "Combination of ibrutinib and ABT-199 in diffuse large B-cell lymphoma and follicular lymphoma", Mol Cancer Ther, 16, pp.1246~1256 (2017)
- Wolowiec D, "Cdk1 is a marker of proliferation in human lymphoid cells", Int J Cancer, 61, pp.381~388 (1995)
- Zhao XF, "Phospho-p70S6K and cdc2", cdk1 as therapeutic targets for diffuse large B-cell lymphoma, 2009, pp.13, 1085~1093
- Zhao MY, "Phospho-p70S6K", p85S6K and cdc2, Clin Cancer Res, pp.2009, 15[DOI]
- Bernasconi M, "Early gene expression changes by Epstein-Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseases", Int J Cancer, 133, pp.2341~2350 (2013)